Abstract | BACKGROUND:
Lung cancer is the most common cancer in the world accounting for 17.6% cancers worldwide. The AAR i n I ndian population varies f r om 0.98-15.55. The aim of t he present study was to analyze areduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer (stage IIIA and III B) using Wobe Mugos E and its evaluation using micronuclei as a cytogenetic marker. Micronuclei, which are cytoplasmic fragments of DNA, have been used as a biological dosimeter to assess DNA damage. MATERIAL AND METHODS: RESULTS: Thirty eight patients were available for final evaluation. Anemia was the most common hematological toxicity observed. Nausea and vomiting were the most common non -hematological toxicity seen. Wobe Mugos E was found to reduce the incidence of leucopenia (p = 0.005), nausea (p=0.004), vomiting (p= 0.003), sensory neuropathy (p = 0.032) and treatment related depression (p= 0.005). A reduction in micronuclei was seen in patients in patients on Wobe Mugos E. (p =0.01). CONCLUSION:
|
Authors | A Bahl, S Chander, P K Julka, G K Rath, D N Sharma, A Kumar, O Nair |
Journal | The Journal of the Association of Physicians of India
(J Assoc Physicians India)
Vol. 54
Pg. 191-5
(Mar 2006)
ISSN: 0004-5772 [Print] India |
PMID | 16800343
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Drug Combinations
- chymotrypsin, papain, trypsin drug combination
- Chymotrypsin
- Trypsin
- Papain
|
Topics |
- Carcinoma, Non-Small-Cell Lung
(drug therapy)
- Chemotherapy, Adjuvant
(adverse effects)
- Chymotrypsin
(therapeutic use)
- Drug Combinations
- Female
- Humans
- India
- Lung Neoplasms
(drug therapy)
- Male
- Micronuclei, Chromosome-Defective
(chemically induced)
- Middle Aged
- Neoadjuvant Therapy
(adverse effects)
- Neoplasm Staging
- Papain
(therapeutic use)
- Trypsin
(therapeutic use)
|